Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-igG2

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Poignard, Pascal ^a,b,c   Moldt, Brian ^a   Maloveste, Karla ^c,h   Campos, Noëlie ^c   Olson, William C ^d   Rakasz, Eva ^e   Watkins, David I ^e,f   Burton, Dennis R ^a,g  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c CNRS   (France)

^d A Subsidiary of Lantheus Holdings   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Amplimmune Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CD4 IMMUNOGLOBULIN G2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; IN VITRO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSMOTIC PUMP; PERIPHERAL BLOOD MONONUCLEAR CELL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; HALF-LIFE; HUMANS; IMMUNOGLOBULIN G; INFUSION PUMPS; MACACA MULATTA; MALE; MUCOUS MEMBRANE; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALIA; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84864398946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042209     Document Type: Article

References (37)

1. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al.((1999)) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:: 4009--4018.
2. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al.((2000)) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:: 207--210.
3. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, et al.((1999)) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5:: 204--210.
4. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al.((2000)) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6:: 200--206.
5. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al.((2001)) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75:: 8340--8347.
6. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Landucci G, et al.((2010)) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:: 1302--1313.
7. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al.((2009)) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:: e1000433.
8. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al.((2009)) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:: 951--954.
9. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, et al.((2007)) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:: 101--104.
10. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, et al.((2002)) Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76:: 2123--2130.
11. Feinberg MB, Moore JP,((2002)) AIDS vaccine models: challenging challenge viruses. Nat Med 8:: 207--210.
12. Lifson JD, Martin MA,((2002)) One step forwards, one step back. Nature 415:: 272--273.
13. Mascola JR, Montefiori DC,((2010)) The role of antibodies in HIV vaccines. Annu Rev Immunol 28:: 413--444.
14. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, et al.((2011)) Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Science Translational Medicine 3:: 81ra36.
15. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al.((2012)) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:: 89--93.
16. Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, et al.((2010)) Macaques Vaccinated with Simian Immunodeficiency Virus SIVmac239{Delta}nef Delay Acquisition and Control Replication after Repeated Low-Dose Heterologous SIV Challenge. J Virol 84:: 9190--9199.
17. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al.((2006)) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7:: 19--23.
18. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, et al.((1995)) Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:: 533--539.
19. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, et al.((1995)) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69:: 6609--6617.
20. Gauduin MC, Allaway GP, Maddon PJ, Barbas CF 3rd, Burton DR, et al.((1996)) Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J Virol 70:: 2586--2592.
21. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, et al.((2001)) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183:: 1121--1125.
22. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, et al.((2011)) MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. The Journal of experimental medicine 208:: 439--454.
23. Gauduin MC, Parren PW, Weir R, Barbas CF 3rd, Burton DR, et al.((1997)) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3:: 1389--1393.
24. Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, et al.((2000)) Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 182:: 1774--1779.
25. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, et al.((2000)) Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 182:: 326--329.
26. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, et al.((2004)) Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 48:: 423--429.
27. Friedrich TC, Watkins DI,((2008)) Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Current opinion in HIV and AIDS 3:: 393--398.
28. Watkins DI,((2008)) The hope for an HIV vaccine based on induction of CD8+ T lymphocytes-a review. Memorias do Instituto Oswaldo Cruz 103:: 119--129.
29. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al.((2009)) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:: 87--91.
30. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, et al.((2009)) Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 83:: 6508--6521.
31. Haase AT,((2010)) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:: 217--223.
32. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al.((2009)) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361:: 2209--2220.
33. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al.((2012)) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England journal of medicine 366:: 1275--1286.
34. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, et al.((2009)) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15:: 901--906.
35. Kowalski WB, Valle RF, Chatterton RT Jr,((1997)) Response of the primate secretory endometrium to subchronic hypercortisolemia. Journal of the Society for Gynecologic Investigation 4:: 152--159.
36. Poignard P, Moulard M, Golez E, Vivona V, Franti M, et al.((2003)) Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 77:: 353--365.
37. Means RE, Greenough T, Desrosiers RC,((1997)) Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. Journal of virology 71:: 7895--7902.